Cary Presant, M.D., F.A.C.C.
I believe in talking with my patients and their family to understand what's most important to them, how the cancer is a challenge to them, and then tailoring Treatments based on precision medicine to help them cure or control their disease and enjoy their lives. My patients are like family to me, so I use the latest advances to cure their illnesses and improve their quality of life in our warm and caring centers.Cary A. Presant, M.D., F.A.C.P., F.A.S.C.O., has been a practicing hematologist and medical oncologist in Southern California since 1979. He has always been involved in laboratory and clinical investigations, and was the director of cancer programs at Washington University St. Louis School of Medicine, the Jewish Hospital of St. Louis, Citrus Valley Health Partners and St. Vincent Medical Center in Los Angeles. Following a post as director of the Department of Medical Oncology at City of Hope, he became president in 1982 of California Cancer Medical Center, a freestanding comprehensive cancer center. In 2004, he merged his center with Wilshire Oncology Medical Group Inc. Currently he is a professor at City of Hope Medical Center, and Clinical Co-director, and Smoking Cessation Champion leader of the National Cancer Institute Moon-Shot Cancer Center Cessation Initiative (C3I) at City of Hope.
Location
West Covina
Suite 303
West Covina, CA 91790
Education & Experience
1972, American Board of Internal Medicine
1972, American Board of Internal Medicine - Hematology
1966, M.D., State University of New York, Buffalo, NY
1962, Undergraduate Studies, University of Buffalo, Buffalo, NY
1970-1972, Hematology-Oncology, Washington University School of Medicine, St. Louis, MO
1967-1969, Hematology/Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD
1972-1973, Postdoctoral Fellow, Biochemistry, Washington University School of Medicine, St. Louis, MO
1969-1970, Internal Medicine, Barnes Hospital, St. Louis, MO
1966-1967, Columbia University Presbyterian Hospital, New York, NY
2018-present, Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, West Covina, CA
2014-2018, Staff Physician, City of Hope, Deaprtment of Medical Oncology & Therapeutics Research, West Covina, CA
1982-present, Chairman, Tumor Board Citrus Valley Medical Center, Queen of the Valley Campus, West Covina, CA
1982-present, Professor of Clinical Medicine, Keck School of Medicine of USC, Los Angeles, CA
1992-2014, President, California Cancer Medical Center, West Covina, CA
1984-1995, Director, Inpatient Oncology Program, Citrus Valley Health Partners, Queen of the Valley Campus, West Covina, CA
1983-1995 Director, Inpatient Oncology, Program and Research Center, Queen of the Valley Hospital, West Covina, CA
1982-1992, Staff Physician, Wilshire Oncology Medical Group Inc., Los Angeles, CA
1980-1982, Associate Director, Cancer Center, City of Hope, Duarte, CA
1979-1982, Director, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, CA
1977-1979, Attending Physician, The Jewish Hospital of St. Louis, St. Louis, MO
1977-1979, Chief, Section of Medical Oncology, Division of Radiation Oncology Mallinckrodt Institute of Radiology, St. Louis, MO
1974-1977, Associate Attending Physician, The Jewish Hospital of St. Louis, St. Louis, MO
1973-1979, Director, Oncology Clinic, The Jewish Hospital of St. Louis, St. Louis, MO
1972-1979, Assistant Professor, Department of Medicine and Radiology, Washington University School of Medicine, St. Louis, MO
1972-1974, Assistant Attending Physician, The Jewish Hospital of St. Louis, St. Louis, MO
1971-1972, Staff Physician, John J. Cochran Veterans Administration Hospital, St. Louis, MO
1970-1973, Instructor, Department of Medicine, Washington University School of Medicine, St. Louis, MO
1970-1971, Consultant, Hematology John J. Cochran Veterans Administration Hospital, St. Louis, MO
1970-1971, Trainee, Hematology, Washington University School of Medicine, St. Louis, MO
1969-1970, Assistant in Medicine, Washington University School of Medicine, St. Louis, MO
1967-1969, Staff Associate, National Cancer Institute, Bethesda, MD
1966-1967, Instructor, Columbia University College of Physicians and Surgeons, New York, NY
Awards & Memberships
Awards
2021, “Top Doctors in America”
2021, Lifetime Achievement Award in Hematology Oncology by Continental Who’s Who
2017, America’s Most Honored Professionals
2016, David King Community Clinical Scientist Award from the Association of Community Cancer Centers
2016, National Patient Choice Award
2015, “Top Oncologist, International Association of Oncologists”
2012, Oncology on Canvas Award Best Photography by a Health Care Professional from Lilly Oncology
“Surviving American Medicine”, International Book Award as top book in health
Memberships
1993, Fellow of the American Society of Clinical Oncology
1974, American Academy of Pain Medicine
1973, American Association for Cancer Research
1973-1995, American College of Physicians
1984, Southwest Oncology Group
1982, California Medical Association
1982, American Federation for Clinical Research
1976, American Cancer Society
1976, International Society of Hematology
1974, American Medical Association
1972, American Society of Hematology
Publications
- Yuan Y, Lee JS, Yost S, et. al. Phase II/III Trial of Palbociclib, Pembrolizumab and Letrozole in Patients with Hormone Receptor Positive Metastatic Breast Cancer. Submitted for publication, 2021.
- Lee-Bitar JS, et. al. Tolerability of Neratinib in Older Adults with HER2 Mutated or HER 2/3 Mutated Metastatic Breast Cancer. Submitted for publication 2021.
- Presant CA, Subbiah S, Upadhyaya, Zheng M. Patient Reported Outcomes after Cannabis Use to Control Symptoms. J Cancer Treatment and Diagn 2020; 4: 6-9.
- Presant CA. Highlights of Virtual ASCO 2020. Oncology Issues 2020; 35: 52-58
- Presant CA, Salgia R, Kulkarni P, et. al. Implementing Lung Cancer Screening and Prevention in Academic Centers, Affiliated Network Offices, and Collaborating Care Sites. J.Clin. Med. 2020; 9: 1820.
- Liu J, Gutierrez E, Tiuari A, et. al. Strategies to Improve Participation of Oder Adults in Cancer Research. J. Clin Med. 2020; 9: 1571.
- C. A. Presant. Best of ASCO 2019, Oncology Issues, 9/1/19
- C.A. Presant. Best of ASCO 2018. Oncology Issues, 9/1/18
- C.A. Presant. Best of ASCO 2017. Oncology Issues, 9/1/17, 38-42.
- Bosserman L, Rogers K, Willis C, Davidson D, Whitworth P, Karimi M, Upadhyaya G, Rutledge J, Hallquist A, Perree M, Presant CA. Application of a Drug-Induced Apoptosis Assay to Identify Treatment Strategies in Recurrent or Metastatic Breast Cancer. PLoS ONE 10(5): e0122609. doi:10.1371/journal.pone.0122609. Published online May 29. 2015.
- Strickland SA, Raptis A, Hallquist A, Rutledge J, Chernick M, Perree M, Talbott MS, Presant CA. 2013. HYPERLINK "http://www.diatech-oncology.com/files/2306/File/Strickland%20et%20al%20Leukemia%20and%20Lymphoma%202013%20vol%2054%20p528-534.pdf" Correlation of the microculture-kinetic drug-induced apoptosis assay with patient outcomes in initial treatment of adult acute myelocytic leukemia. Leuk Lymphoma. 54: 528-34.
- Bosserman L, Prendergast F, Herbst R, Fleisher M, Salom E, Strickland S, Raptis A, Hallquist A, M. Perree M, Rajurkar S, Karimi M, Rogers K, Davidson D, Willis C, Penalver M, Homesley H, Burrell M, Garrett A, Rutledge J, Chernick M, Presant CA. 2012. HYPERLINK "http://www.diatech-oncology.com/files/2306/File/Cancer%20Res-2012-Bosserman-3901-5%202.pdf" The microculture-kinetic (MiCK) assay: the role of a drug-induced apoptosis assay in drug development and clinical care.